SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as community members rally behind the revival of classic internet rage comics, emphasizing the project's ownership of original cultural domains and its commitment to building on the Solana network. Supporters are focused on long-term conviction, actively creating and sharing memes to fuel memetic power and establish the token as a leading, authentic OG meme.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is seeing intense community debate following disappointing quarterly earnings and the debut shareholder letter from new CEO Greg Abel, with investors sharply divided between those alarmed by the company's underperformance and those viewing the recent pullback as a strategic buying opportunity for a firm sitting on a record cash pile.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in conversation as a satirical, community-driven project that leverages long-standing internet lore, with many proponents highlighting its cultural endurance and potential to challenge established market narratives. Investors are actively debating its status as a parody of traditional finance, while the community emphasizes the project's accessibility and its origins as a long-term satirical movement.

Maulcoin

Maulcoin is capturing market attention as the community rallies around its organic, meme-driven growth and a rejection of traditional, high-pressure marketing tactics. Investors are actively discussing the project's grassroots origins and the upcoming milestones intended to drive momentum and long-term engagement.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant social media buzz due to its extremely low circulating supply, with community members actively discussing its potential for a massive price appreciation as a DePIN and DeFi integration play. Investors are focused on accumulating the asset, viewing its scarcity as a catalyst for a potential major breakout if trading volume increases.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

Ghost is trending as investors debate its long-term utility against accusations of being a pump-and-dump scheme, with community members actively discussing upcoming project developments and potential partnerships. Proponents are focusing on its role as a privacy-focused layer within the Solana ecosystem, while skeptics warn of volatility and compare recent price action to past failed projects.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining significant momentum as investors draw parallels to the cultural longevity of iconic meme-based tickers like Doge and Pepe. The community is actively discussing the asset's potential for sustainable growth, emphasizing its recognizable branding as a key driver for long-term relevance in the memecoin space.

What is the project about?&nbsp;  Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security:&nbsp;As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture:&nbsp;Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack:&nbsp;Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach:&nbsp;Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base:&nbsp;As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs:&nbsp;Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion:&nbsp;ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design:&nbsp;With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance:&nbsp;Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

Zen Crypto is gaining momentum as market participants increasingly view it as a high-potential privacy asset following recent infrastructure upgrades and its migration to the Base network. Community discussion is heavily focused on the coin's limited circulating supply and historical chart patterns, with many investors actively accumulating during dips while anticipating a major breakout tied to broader privacy-sector trends.

DNP Select Income Fund, Inc. is a closed-end investment fund. Its investment objectives are current income, long-term growth of income and capital appreciation by investing primarily in a portfolio of equity and fixed income securities of companies in the public utilities industry. the company was founded on January 21, 1986 and is headquartered in Chicago, IL.

DNP Select Income Fund Inc.

Investors are closely monitoring DNP Select Income Fund due to its reputation for consistent monthly dividends and its utility-focused portfolio, which some argue is well-positioned for future energy demand. The community frequently highlights the stock's stability as a long-term income play while actively debating optimal entry points and the mechanics of dividend reinvestment programs.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors (NXPI) is currently attracting significant attention as investors weigh a major geopolitical escalation in U.S. semiconductor export controls against the company's long-term growth potential in automotive and IoT markets. While some analysts highlight the stock's valuation as a potential buying opportunity amidst broader sector volatility, the community remains actively divided, debating whether upcoming regulatory pressures or cyclical demand shifts present a greater risk to the share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insmed (NASDAQ:INSM) Upgraded to "Moderate Buy" at Raymond James Financial

Raymond James Financial raised shares of Insmed to a "moderate buy" rating in a research report on Thursday...

Raymond James Financial Initiates Coverage on Insmed (NASDAQ:INSM)

Raymond James Financial started coverage on Insmed in a research note on Friday. They issued an "outperform" rating and a $200.00 target price on the stock...

What is HC Wainwright's Estimate for Insmed FY2027 Earnings?

Insmed, Inc. (NASDAQ:INSM - Free Report) - Research analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Insmed in a research report issued on Wednesday, April 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will earn $0.88 per shar...

Insmed (NASDAQ:INSM) CEO Sells $1,746,290.78 in Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of...

Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the company's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $163.22...

Insmed Ends Brinsupri Development in Skin Disease Post Study Failure

INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

Insmed Drug Misses Primary Goal, Program Axed

Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to Brinsupri and Arikayce growth drivers.read more...

<ul class="summary-bullets"><li>Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa</li><li>Martina Flammer, Chief Medical Officer of Insmed, said that the company was disappointed with the results.</li><li>According to data from Koyfin, &nbsp;all of the 20 analysts covering INSM stock rate it ‘Buy’ or higher.</li></ul>Insmed Incorporated (INSM) said on Tuesday that its mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its goals.Shares of the company fell 2% after hours.<h2 class="st-heading-2">Study Results</h2>The mid-stage trial was aimed at evaluating the safety and efficacy of brensocatib in adults with moderate to severe hidradenitis suppurativa, a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses. &nbsp;The trial did not meet the primary or secondary endpoints in either the 10 mg or 40 mg treatment arms though the drug was well tolerated, the company said. The study enrolled 214 patients and its primary goal was a reduction in total abscess and inflammatory nodule at 16 weeks.Participants of the study experienced a 45.5% and 40.3% reduction from baseline in total abscess and inflammatory nodule (AN) count in the brensocatib 10 mg and 40 mg arms, respectively, compared to a 57.1% reduction in the placebo arm, the company said.Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa. Martina Flammer, Chief Medical Officer of Insmed, said that the company is “disappointed” with the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around INSM stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, all 20 analysts covering INSM stock rate it ‘Buy’ or higher. The stock has an average 12-month price target of $214.79, representing a potential upside of about 32% from last closing price.The company currently has two approved therapies, including Brinsupri for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older, and Arikayce for the treatment of certain Mycobacterium avium complex (MAC) lung infections.<a href="https://stocktwits.com/symbol/INSM">INSM stock</a> has more than doubled over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gopro-shares-edge-up-after-hours-on-23-percent-layoff-announcement/cZJB2feRIqd">GoPro Shares Edge Up After-Hours On 23% Layoff Announcement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study 

The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms, though the drug was well tolerated, the company said. 

Equity

The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms, though the drug was well tolerated, the company said. 


Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Provides Clinical Update on Phase 2b CEDAR Study Insmed Provides Clinical Update on Phase 2b CEDAR Study PR Newswire BRIDGEWATER, N.J., April 7, 2026 Study Did Not MeetPrimary or Secondary...

The death cross is one of the most closely watched patterns in technical analysis. It forms when a stock's 50-day moving average crosses below its 200-day moving average. Image courtesy: Getty Images

INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors

Bearish technical signals flash across three stocks, but Wall Street analysts still see meaningful upside ahead.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM
Insmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INSM News

INSMInsmed Inc